Merus is committed to discovering and developing new treatments. Every day, we bring a sense of urgency and a passion to help patients.

BIZENGRI^® has been approved for treatment of adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy.

This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Patients and/or providers who have questions about access to and insurance coverage for BIZENGRI^® should contact 1-844-637-8787.